

Disclosure of Competing Interests

The American Journal of Psychiatry has implemented a policy requiring its editors to disclose any potential competing interests of \$5,000 or more, including consulting with pharmaceutical companies or receiving honoraria or travel expenses from them. During the past calendar year these competing interests were as follows:

- Robert Freedman, M.D., had no competing interests.
- David A. Lewis, M.D., received investigator-initiated research support from Pfizer, Eli Lilly and Merck, and served as a consultant to Pfizer.
- Robert Michels, M.D., had no competing interests.
- Daniel S. Pine, M.D., had no competing interests.
- Susan K. Schultz, M.D., had no competing interests.
- Carol A. Tamminga, M.D., received consultant income from Avera, Intracellular Therapies, and Neurogen; she is an ad hoc consultant for J&J; receives investigator-initiated research support from Acadia; and serves as a consultant to the TURNS project at the University of California at Los Angeles.